Markets
US-TECHNOLOGY-LIFESTYLE-ELECTRONICS
A Palantir Technologies Skykit (Patrick T. Fallon/Getty Images)

Retail traders’ zest for Palantir put to the test as earnings await

High multiples usually mean high expectations, but Palantir’s profits are expected to nearly halve year on year.

It’s earnings day for Palantir, arguably the hottest retail stock of the moment.

That steadfast retail shareholder base came in handy after Palantir endured a pretty gnarly 19% drop between January 3 and January 13 amid a wobble in confidence around the highest flyers of the AI era.

Retail traders swooped in to buy the dip and for weeks they’ve been laughing, as the stock recovered its loss and then some. Shares recently hit record highs. Nice trade.

Still, the nagging question posed by Palantir’s insane valuation multiples — forward PE (173x), trailing PE (418x), price-to-forward sales (53x) — remains: is there a snowball’s chance in hell of Palantir’s sales, profits, and margins ever reaching a level that would come anywhere near justifying the company’s nearly $190 billion market valuation?

For what it’s worth, that level of market cap puts Palantir, which has been public for less than five years and in the black for just two, ahead of perennially profitable icons of corporate America like AT&T, Verizon, and Pfizer, to name a few.

Of course, there’s no way that today’s numbers — due around 5 p.m. ET — will answer that question conclusively. Even if Palantir blew the doors off the hinges and posted sales well above the consensus expectation of $771 million and a far fatter profit than the somewhat piddling $48 million that’s projected, the stock would still be laughably overvalued by any traditional metric.

As far as the details, analysts and traders are going to be especially interested in whether Palantir sees a Q4 fillip in sales to corporate clients rather than its larger business of selling defense and intelligence software to governments and militaries. Palantir has been talking up the demand for its AI software products from private-sector buyers recently.

But if the numbers fall far short, it stands to reason it could take some wind out of the stock’s sails.

Shareholders may rightly wonder whether the superheated rhetoric emanating from Palantir executives might actually be an attempt to sex up a fairly standard software business. A bad quarter could also prompt shareholders to take a second look at the fact that the CEO has picked up the pace of his share sales (albeit through a prearranged stock sale program) and has dumped over $2 billion worth of Palantir stock in the last six months, according to one analyst.

Or maybe not. In many ways, we’re in something of a LOL-nothing-matters market.

Case in point: traditional business metrics like sales and profits have proven a remarkably poor guide predictor for Tesla’s share price recently, so much so that flummoxed Wall Street analysts are going public with the fact that they’re at a loss to explain the stock’s rise in the face of obviously ugly earnings last week.

Tesla is an interesting comp for Palantir. Both companies are wealth vehicles of right-wing oligarchs with close ties to the Trump administration. Both have rabid contingents of retail shareholder and outspoken, charismatic CEOs. And both have crucial business issues that hinge on federal government policies, whether it’s in the form of the federal EV tax credits that incentivize sales of electric offerings like Teslas or the fact that Palantir’s single largest customer is the US government. (Oh and there’s also Musk’s other venture, SpaceX, which is a major government contractor.)

Oddly enough, these two companies also happen to be the top two stocks in the S&P 500 (closely followed by Taser maker Axon) since President Trump won the election in November, suggesting that at least some investors are betting on benefits for Tesla and Palantir under the new administration that traditional business metrics don’t quite capture.

Ain’t the free market grand.

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.